Molecular structure of Bupivacaine hydrochloride, CAS Number: 18010-40-7
Bupivacaine hydrochloride (CAS 18010-40-7)
Alternate Names:
1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide
Application:
Bupivacaine hydrochloride is a Na+ channel blocker
CAS Number:
18010-40-7
Purity:
>99%
Molecular Weight:
324.89
Molecular Formula:
C18H28N2O•HCl
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Bupivacaine hydrochloride is widely studied in the field of sensory neuron research. It is of particular interest in understanding the mechanisms by which sodium channel blockers affect nerve impulse transmission. In in vitro studies, bupivacaine hydrochloride is used to examine the pharmacological effects of sodium channel modulation on neuronal excitability and conduction. Studies involving bupivacaine hydrochloride contribute to a greater understanding of pain signaling pathways and the role of sodium channels in these processes. The hydrochloride salt form of this compound is favored in research applications due to its enhanced solubility, which facilitates its application in various experimental models.
Bupivacaine hydrochloride (CAS 18010-40-7) References
- Does Liposomal Bupivacaine Have Any Advantage Over Bupivacaine Hydrochloride for Intercostal Nerve Blocks in Minimally Invasive Thoracic Surgery? | Campos, JH. and Seering, M. 2021. J Cardiothorac Vasc Anesth. 35: 1399-1403. PMID: 33563528
- Liposomal bupivacaine versus bupivacaine hydrochloride: are we changing the outcomes? | Abd-Elsayed, A. 2021. Reg Anesth Pain Med. 46: 499. PMID: 33837137
- The analgesic efficacy of liposomal bupivacaine compared with bupivacaine hydrochloride for the prevention of postoperative pain: a systematic review and meta-analysis with trial sequential analysis. | Dinges, HC., et al. 2021. Reg Anesth Pain Med. 46: 490-498. PMID: 33837139
- Study of Peri-Articular Anaesthetic for Replacement of the Knee (SPAARK): statistical analysis plan for a randomised controlled trial assessing the effectiveness of peri-articular liposomal bupivacaine plus bupivacaine hydrochloride compared with bupivacaine hydrochloride alone. | Stokes, JR., et al. 2021. Trials. 22: 346. PMID: 34001205
- Injectable thermoresponsive gels offer sustained dual release of bupivacaine hydrochloride and ketorolac tromethamine for up to two weeks. | Abdeltawab, H., et al. 2021. Int J Pharm. 604: 120748. PMID: 34051318
- Liposomal bupivacaine use in exploratory lingual nerve microsurgery: does liposomal bupivacaine use decrease postoperative pain and opioid consumption compared to bupivacaine hydrochloride? A pilot study. | Jacobus, D., et al. 2021. Quintessence Int. 52: 812-818. PMID: 34269041
- Stability and compatibility of admixtures containing bupivacaine hydrochloride and ketorolac tromethamine for parenteral use. | Abdeltawab, H., et al. 2023. Eur J Hosp Pharm. 30: e48-e54. PMID: 34663584
- Liposomal bupivacaine provides longer duration analgesia than bupivacaine hydrochloride in an adjustable sole-pressure model of equine lameness. | Moorman, VJ., et al. 2022. Am J Vet Res. 83: 298-304. PMID: 35092669
- Efficacy of Liposomal Bupivacaine and Bupivacaine Hydrochloride vs Bupivacaine Hydrochloride Alone as a Periarticular Anesthetic for Patients Undergoing Knee Replacement: A Randomized Clinical Trial. | Hamilton, TW., et al. 2022. JAMA Surg. 157: 481-489. PMID: 35385072
- Thermosensitive injectable graphene oxide/chitosan-based nanocomposite hydrogels for controlling the in vivo release of bupivacaine hydrochloride. | Al Homsi, R., et al. 2022. Int J Pharm. 621: 121786. PMID: 35500689
- The Influence of Diabetic Peripheral Neuropathy on the Duration of Sciatic Nerve Block with 1.3% Liposomal Bupivacaine and 0.25% Bupivacaine Hydrochloride in a Mouse Model. | Markova, L., et al. 2022. Pharmaceutics. 14: PMID: 36145571
- Safety and Efficacy of Long-Acting Liposomal Bupivacaine Plus Bupivacaine Hydrochloride for Dorsal Penile Block During Ambulatory Pediatric Urologic Surgery. | Gabrielson, AT., et al. 2023. Urology.. PMID: 36997075
- A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a bupivacaine hydrochloride implant in patients undergoing abdominoplasty. | Beaton, AC., et al. 2023. Reg Anesth Pain Med.. PMID: 37076252
Activator of:
KCNQ2.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Bupivacaine hydrochloride, 1 g | sc-252524 | 1 g | $104.00 | |||
Bupivacaine hydrochloride, 5 g | sc-252524A | 5 g | $171.00 | |||
Bupivacaine hydrochloride, 50 g | sc-252524B | 50 g | $785.00 | |||
Bupivacaine hydrochloride, 100 g | sc-252524C | 100 g | $1413.00 |